ReP USP - Resultado da busca

Artigo de periodico
SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension (2017)
Galiè, Nazzareno; Jansa, Pavel; Pulido, Tomás; Channick Richard N.; Delcroix, Marion; Ghofrani, Hossein-Ardeschir; Le Brun, Franck-Olivier; Mehta, Sanjay; Perchenet, Loïc; Rubin Lewis J.; Sastry, B.K.S.; Simonneau, Gérald; Sitbon, Olivier; Souza, Rogério; Torbicki, Adam
Source: European Heart Journal. Unidade: FM
Subjects: MORTALIDADE, CATETERISMO CARDÍACO, ESTUDOS RANDOMIZADOS, HIPERTENSÃO PULMONAR
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
GALIÈ, Nazzareno et al. SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension. European Heart Journal, v. 38, n. 15, p. 1147-1155, 2017Tradução . . Disponível em: https://doi.org/10.1093/eurheartj/ehx025. Acesso em: 11 nov. 2024.
APA
Galiè, N., Jansa, P., Pulido, T., Channick Richard N.,, Delcroix, M., Ghofrani, H. -A., et al. (2017). SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension. European Heart Journal, 38( 15), 1147-1155. doi:10.1093/eurheartj/ehx025
NLM
Galiè N, Jansa P, Pulido T, Channick Richard N., Delcroix M, Ghofrani H-A, Le Brun F-O, Mehta S, Perchenet L, Rubin Lewis J., Sastry BKS, Simonneau G, Sitbon O, Souza R, Torbicki A. SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension [Internet]. European Heart Journal. 2017 ; 38( 15): 1147-1155.[citado 2024 nov. 11 ] Available from: https://doi.org/10.1093/eurheartj/ehx025
Vancouver
Galiè N, Jansa P, Pulido T, Channick Richard N., Delcroix M, Ghofrani H-A, Le Brun F-O, Mehta S, Perchenet L, Rubin Lewis J., Sastry BKS, Simonneau G, Sitbon O, Souza R, Torbicki A. SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension [Internet]. European Heart Journal. 2017 ; 38( 15): 1147-1155.[citado 2024 nov. 11 ] Available from: https://doi.org/10.1093/eurheartj/ehx025
Artigo de periodico
Effect of macitentan on hospitalizations: Results from the SERAPHIN trial (2015)
Channick, Richard N.; Delcroix, Marion; Ghofrani, Hossein-Ardeschir; Hunsche, Elke; Jansa, Pavel; Le Brun, Franck-Olivier; Mehta, Sanjay; Pulido, Tomás; Rubin, Lewis J.; Sastry, B. K. S.; Simonneau, Gérald; Sitbon, Olivier; Souza, Rogério de; Torbicki, Adam; Galiè, Nazzareno
Source: JACC Heart failure. Unidade: FM
Subjects: HIPERTENSÃO PULMONAR, FÁRMACOS/SISTEMA RESPIRATÓRIO, HOSPITALIZAÇÃO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CHANNICK, Richard N. et al. Effect of macitentan on hospitalizations: Results from the SERAPHIN trial. JACC Heart failure, v. 3, n. 1, p. 1-8, 2015Tradução . . Disponível em: https://doi.org/10.1016/j.jchf.2014.07.013. Acesso em: 11 nov. 2024.
APA
Channick, R. N., Delcroix, M., Ghofrani, H. -A., Hunsche, E., Jansa, P., Le Brun, F. -O., et al. (2015). Effect of macitentan on hospitalizations: Results from the SERAPHIN trial. JACC Heart failure, 3( 1), 1-8. doi:10.1016/j.jchf.2014.07.013
NLM
Channick RN, Delcroix M, Ghofrani H-A, Hunsche E, Jansa P, Le Brun F-O, Mehta S, Pulido T, Rubin LJ, Sastry BKS, Simonneau G, Sitbon O, Souza R de, Torbicki A, Galiè N. Effect of macitentan on hospitalizations: Results from the SERAPHIN trial [Internet]. JACC Heart failure. 2015 ; 3( 1): 1-8.[citado 2024 nov. 11 ] Available from: https://doi.org/10.1016/j.jchf.2014.07.013
Vancouver
Channick RN, Delcroix M, Ghofrani H-A, Hunsche E, Jansa P, Le Brun F-O, Mehta S, Pulido T, Rubin LJ, Sastry BKS, Simonneau G, Sitbon O, Souza R de, Torbicki A, Galiè N. Effect of macitentan on hospitalizations: Results from the SERAPHIN trial [Internet]. JACC Heart failure. 2015 ; 3( 1): 1-8.[citado 2024 nov. 11 ] Available from: https://doi.org/10.1016/j.jchf.2014.07.013
Artigo de periodico
Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension (2013)
Pulido, Tomás; Adzerikho, Igor; Channick, Richard N.; Delcroix, Marion; Galiè, Nazzareno; Ghofrani, Hossein-Ardeschir; Jansa, Pavel; Jing, Zhi-Cheng; Le Brun, Franck-Olivier; Mehta, Sanjay; Mittelholzer, Camilla M.; Perchenet, Loïc; Sastry, B. K. S.; Sitbon, Olivier; Souza, Rogério; Torbicki, Adam; Zeng, Xiaofeng; Rubin, Lewis J.; Simonneau, Gérald
Source: The New England Journal of Medicine. Unidade: FM
Subjects: HIPERTENSÃO PULMONAR (MORTALIDADE), CATETERISMO CARDÍACO, CONDUTAS TERAPÊUTICAS, MEDICAMENTO (EFEITOS ADVERSOS), MÉTODO DUPLO-CEGO, PLACEBOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PULIDO, Tomás et al. Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension. The New England Journal of Medicine, v. 369, n. 9, p. 809-818, 2013Tradução . . Disponível em: http://www.nejm.org/doi/pdf/10.1056/NEJMoa1213917. Acesso em: 11 nov. 2024.
APA
Pulido, T., Adzerikho, I., Channick, R. N., Delcroix, M., Galiè, N., Ghofrani, H. -A., et al. (2013). Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension. The New England Journal of Medicine, 369( 9), 809-818. doi:10.1056/NEJMoa1213917
NLM
Pulido T, Adzerikho I, Channick RN, Delcroix M, Galiè N, Ghofrani H-A, Jansa P, Jing Z-C, Le Brun F-O, Mehta S, Mittelholzer CM, Perchenet L, Sastry BKS, Sitbon O, Souza R, Torbicki A, Zeng X, Rubin LJ, Simonneau G. Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension [Internet]. The New England Journal of Medicine. 2013 ; 369( 9): 809-818.[citado 2024 nov. 11 ] Available from: http://www.nejm.org/doi/pdf/10.1056/NEJMoa1213917
Vancouver
Pulido T, Adzerikho I, Channick RN, Delcroix M, Galiè N, Ghofrani H-A, Jansa P, Jing Z-C, Le Brun F-O, Mehta S, Mittelholzer CM, Perchenet L, Sastry BKS, Sitbon O, Souza R, Torbicki A, Zeng X, Rubin LJ, Simonneau G. Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension [Internet]. The New England Journal of Medicine. 2013 ; 369( 9): 809-818.[citado 2024 nov. 11 ] Available from: http://www.nejm.org/doi/pdf/10.1056/NEJMoa1213917

USP Schools

ReP

Filtros

Authors

Subjects

Indexado em

Non normalized affiliation

Countries of institutions of collaboration